Compounds and methods of use Number:7,435,823 from the United States Patent and Trademark Office (PTO) owispatent Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.<H Compounds, methods, Compounds, and, m, 7435823.html, Patent, pto, 7435823

Title: Compounds and methods of use

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Patent Number: 7,435,823 Issued on 10/14/2008 to Potashman, et al.

Inventors: Potashman; Michele (Cambridge, MA), Kim; Tae-Seong (Thousand Oaks, CA), Bellon; Steven (Wellesley, MA), Booker; Shon (Thousand Oaks, CA), Cheng; Yuan (Newbury Park, CA), Kim; Joseph L. (Wayland, MA), Tasker; Andrew (Simi Valley, CA), Xi; Ning (Thousand Oaks, CA), Xu; Shimin (Ventura, CA), Harmange; Jean-Christophe (Andover, MA), Borg; George (Cambridge, MA), Weiss; Matthew (Boston, MA), Hodous; Brian L. (Cambridge, MA), Graceffa; Russell (Hampton, NH), Buckner; William H. (Arlington, MA), Masse; Craig E. (Cambridge, MA), Choquette; Deborah (Medford, MA), Martin; Matthew W. (Cambridge, MA), Germain; Julie (Medford, MA), DiPietro; Lucian V. (Gloucester, MA), Chaffee; Stuart C. (Cambridge, MA), Nunes; Joseph J. (Andover, MA), Buchanan; John L. (Brookline, MA), Habgood; Gregory J. (Merrimac, MA), McGowan; David C. (Woluwe St. Pierre, BE), Whittington; Douglas A. (Waltham, MA), La; Daniel (Brookline, MA), Patel; Vinod F. (Acton, MA)
Assignee: Amgen Inc. (Thousand Oaks, CA)

Appl. No.: 11/042,634

Filed: January 24, 2005

Related U.S. Patent Documents


Application Number	Filing Date	Patent Number	Issue Date
60538691	Jan., 2004

Current U.S. Class: 546/153 ; 544/105; 544/99; 546/15

Current International Class: C07D 215/38 (20060101); C07D 265/34 (20060101)

Field of Search: 544/99,105 546/153,15

References Cited [Referenced By]

U.S. Patent Documents


3755332	August 1973	Wasley et al.
4916135	April 1990	Effland et al.
5580870	December 1996	Barker et al.
5866572	February 1999	Barker et al.
5965563	October 1999	Buzzetti et al.
6143764	November 2000	Kubo et al.
6265398	July 2001	Braun et al.
6313129	November 2001	Uckun et al.
6358962	March 2002	Uckun et al.
6399602	June 2002	Barker et al.
6469013	October 2002	Uckun et al.
6495556	December 2002	Uckun et al.
6573289	June 2003	Tasaka et al.
7312330	December 2007	Kelly et al.
2003/0018029	January 2003	Barker et al.
2003/0165873	September 2003	Come et al.
2004/0053908	March 2004	Funahashi et al.
2004/0242603	December 2004	Fujiwara et al.

Foreign Patent Documents


860433	Aug., 1998	EP
1411046	Apr., 2004	EP
1415987	May., 2004	EP
1 548 008	Jun., 2005	EP
WO 96/23774	Aug., 1996	WO
WO 96/29301	Sep., 1996	WO
WO 96/29305	Sep., 1996	WO
WO 97/03069	Jan., 1997	WO
WO97/22596	Jun., 1997	WO
WO 99/35132	Jul., 1999	WO
WO 99/54309	Oct., 1999	WO
WO 99/61428	Dec., 1999	WO
WO 00/10981	Mar., 2000	WO
WO 00/47212	Aug., 2000	WO
WO 00/56720	Sep., 2000	WO
WO 00/61580	Oct., 2000	WO
WO 01/70673	Sep., 2001	WO
WO 01/70734	Sep., 2001	WO
WO 02/22607	Mar., 2002	WO
WO 02/22608	Mar., 2002	WO
WO 02/30924	Apr., 2002	WO
WO 02/076976	Oct., 2002	WO
WO02/098426	Dec., 2002	WO
WO 03/040108	May., 2003	WO
WO 03/040109	May., 2003	WO
WO 03/064413	Aug., 2003	WO
WO 03/082272	Oct., 2003	WO
WO 2004/029045	Apr., 2004	WO
WO2004/043379	May., 2004	WO
WO 2004/078114	Sep., 2004	WO
WO 2004/085425	Oct., 2004	WO
WO 2004/098604	Nov., 2004	WO
WO2005/021553	Mar., 2005	WO
WO2005/037285	Apr., 2005	WO

Other References

US. Appl. No. 11/412,302, filed Apr. 2005, Kim. cited by examiner .
Paolo M. Comoglio, "Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells", Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the C-Met Receptor, eds. Goldberg and Rosen, Birkhauser Verlag Basel, Switzerland, 131-165 (1993). cited by other .
Connell et al., "Patent focus on cancer chemotherapeutics. II Angiogenesis agents: Apr. 2000-Sep. 2000", Expert Opinion on Therapeutic Patents, 11(1):77-114 (2001). cited by other .
Anderson et al., Involvement of the protein tyrosine kinase p56.sup.lck in T cell signaling and thymocyte development, Advances in Immunology, 56:151-178 (1994). cited by other .
Appleby et al., Defective T cell receptor signaling in mice lacking the thymic isoform of p59.sup.fyn, Cell, 70:751-763 (1992). cited by other .
Asami et al., Purification and characterization of hepatocyte growth factor from injured liver of carbon tetrachloride-treated rats, Journal of Biochemistry, 109:8-13 (1991). cited by other .
Asano et al., Silver halide color photographic materials, Abstract 113:181318 (1990). cited by other .
Boehm et al., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, 390:404-407 (1997). cited by other .
Bolen et al., Leukocyte protein tyrosine kinases: Potential targets for drug discovery, Annu. Rev. Immunology, 15:371-404 (1997). cited by other .
Brazhko et al., Investigations of the biological activity 4-thioquinolines. Abstract 135:189745, 2001. cited by other .
Bussolino et al., Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth, The Journal of Cell Biology, 119(3):629-641 (1992). cited by other .
Chan et al., Isoforms of human HGF and their biological activities, Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the C-Met Receptor, pp. 67-79, Goldberg and Rosen (Eds.), Birkhauser Verlag Basel, Switzerland (1993). cited by other .
Chatterjee, A.K., 4-Aminoquinolines. III. Some 4-(quinolylamino)quinolines, Science and Culture 23:195 (1957). cited by other .
Cockerill et al., Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2, Bioorganic & Medicinal Chemistry Letters, 11:1401-1405 (2001). cited by other .
Di Renzo et al., Selective expression of the Met/HGF receptor in human central nervous system microglia, Oncogene, 8:219-222 (1992). cited by other .
Gibson et al., Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumor activity of novel quinazolines, Bioorganic & Medicinal Chemistry Letters, 7(21):2723-2728 (1997). cited by other .
Giordano et al., Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene, Proceedings of the National Academy of Sciences, USA, 90:649-653 (1993). cited by other .
Goldman et al, Defective expression of p56lck in an infant with severe combined immunodeficiency, Journal of Clinical Investigations, 102(2):421-429 (1998). cited by other .
Han et al., Characterization of the DNF15S2 locus on human chromosome 3: Identification of a gene coding for four kringle domains with homology to hepatocyte growth factor, Biochemistry, 30:9768-9780 (1991). cited by other .
Igawa et al., Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells, Biochemical and Biophysical Research Communications, 174(2):831-838 (1991). cited by other .
Jeffers et al., Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis, J. Mol. Med., 74:505-513 (1996). cited by other .
Kane et al., Signal transduction by the TCR for antigen, Current Opinion in Immunology, 12:242-249 (2000). cited by other .
Kasai et al., Flexible coordination networks with fluorinated backbones, remarkable ability for induced-fit enclathration of organic molecules, Journal of American Chemical Society, 122:2140-2141 (2000). cited by other .
Konishi et al., Preparation of thioquinoline derivatives as antibacterial agents for Helicobacter pylori, Chemical Abstracts 125:247631, 1996. cited by other .
Lempert-Streter et al., The synthesis of di(1-isoquinolinyl) and di(4-quinazolinyl) disulfides form 1(2H)-isoquinolinethiones and 4(3H)-quinazolinethiones, respectively, with tosyl chloride and sodium ethoxide, Acta Chemica Hungarica, 112(1):83-87 (1983). cited by other .
Makisumi, Yasuo, The Thio-claisen rearrangement of allyl 4-quinolyl sulfides, Tetrahedron Letters, 51:6399-6403 (1966). cited by other .
Maslankiewicz, M.J., Reactions of .beta.- and .gamma.-quinolinyl sulfides with a nitrating mixture, Polish Journal of Chemistry, 68(12):2545-2552 (1994). cited by other .
Matsumoto et al., Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth, Biochemical and Biophysical Research Communications, 176(1):45-51 (1991). cited by other .
Matsunaga et al., C.sub.17,20-lyase inhibitors. Part 2:Design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C.sub.17,20-lyase inhibitors, Bioorganic & Medicinal Chemistry, 12:4313-4336 (2004). cited by other .
Maulik et al., Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition, Cytokine & Growth Factor Reviews, 13:41-59 (2002). cited by other .
Montesano et al., Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors, Cell, 66:697-711 (1991). cited by other .
Monti et al., IV. Abstract 55:2681, 1959. cited by other .
Moszew et al., Thermal reactions of .gamma.-thiols in pyridine and quinoline series. Abstract 77:164418, 1972. cited by other .
Nakamura et al., Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats, Biochemical and Biophysical Research Communications, 122(3):1450-1459 (1984). cited by other .
Naldini et al., Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor, EMBO Journal, 10:2867-2878 (1991). cited by other .
Park et al., Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors, Proceedings of the National Academy of Sciences, USA, 84:6379-6383 (1987). cited by other .
Renfrew, Alice G., Studies in the Quinoline Series. IV. Quinolyl Mercaptans and Sulfides, J. American Chemical Society, 1433-1436 (1946). cited by other .
Di Renzo et al., Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas, Oncogene, 7:2549-2553 (1992). cited by other .
Rubin et al., A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor, Proceedings of the National Academy of Sciences, USA, 88:415-419 (1991). cited by other .
Sinyak et al., The synthesis and biological properties of the derivatives of 4-heterylmercaptoquinazoline, Khimiko-Farmatsevticheskii Zhurnal, 20(2), 168-171 (1986). Abstract 104:199594. cited by other .
Solbreux et al., Extrahepatic bile duct growth in mice repeatedly injected with human normal serum, IgA-deficient serum or purified secretory IgA, Hepatology, 13:735-742 (1991). cited by other .
Soriano et al., Targeted disruption of the C-src proto-oncogene leads to osteopetrosis in mice, Cell, 64:693-702 (1991). cited by other .
Stern et al., Epithelial scatter factor and development of the chick embryonic axis, Development 110:1271-1284 (1990). cited by other .
Stoker et al., Scatter factor is a fibroblast-derived modulator of epithelial cell mobility, Nature, 327:239-242 (1987). cited by other .
Thakore, P.V. et al., Studies in the synthesis of quinoline derivatives. Part VIII. Synthesis of 4:3'-methylenebis(2,2'-dichloro-4'-methylquinoline) derivatives, Journal of the Indian Chemical Society, 54(12):1204-1206 (1977). cited by other .
Turner et al., Signalling through the high-affinity IgE receptor Fc.epsilon. Rl, Nature, 402:B24-B30 (1999). cited by other .
Vicentini et al., Fgr deficiency results in defective eosinophil recruitment to the lung during allergic airway inflammation, The Journal of Immunology, 168:6446-6454 (2002). cited by other .
Weidner et al., Scatter Factor: Molecular characteristics and effect on the invasiveness of epithelial cells, The Journal of Cell Biology, 111:2097-2108 (1990). cited by other .
Wyszomirski et al., Conformations of monosubstituted and disubstituted 3,4'-, 3,3'- and 4,4'-diquinolinyl sulfides studied by NMR spectroscopy, Phosphorus, Sulfur, and Silicon, 95-96:415-416 (1994). cited by other .
Zhang et al., Synthesis and antimalarial activity of 2-dialkylaminomethyl-4-(heterocyclic amino)-5,6,7,8-tetrahydronaphthol derivatives. Abstract 103:87753, 1985. cited by other .
Zhang et al., Synthesis and SAR of potent EGFR/erbB2 dual inhibitors, Bioorganic & Medicinal Chemistry Letters, 14:111-114 (2004). cited by other .
Breier et al., The role of vascular endothelial growth factor in blood vessel formation, Trends in Cell Biology, 6:454-456 (1996). cited by other.

Primary Examiner: Seaman; D. Margaret
Attorney, Agent or Firm: Bulock; Joseph W. Hermenau; Ronald S.

Parent Case Text

This application claims the benefit of U.S. Provisional Application No. 60/538,691 filed Jan. 23, 2004, which is hereby incorporated by reference.

Claims

What is claimed is:

1. A compound of Formula I' ##STR00977## wherein R is selected from a) substituted or unsubstituted aryl, b) substituted or unsubstituted heterocyclyl, c) substituted or unsubstituted cycloalkyl, d) substituted or unsubstituted cycloalkenyl, e) H, f) substituted or unsubstituted alkyl, g) substituted or unsubstituted alkenyl, h) substituted or unsubstituted alkynyl, i) alkylaminocarbonyl, j) aminocarbonyl, and k) cyano; wherein R.sup.1 is ##STR00978## wherein ring T is selected from phenyl and 5-6-membered heteroaryl; wherein Z is selected from N or CR.sup.x; wherein R.sup.x is selected from H, CN, NH.sub.2, F, alkylcarbonylamino, and alkylaminocarbonyl; wherein R.sup.10 is one or more substituents selected from H, C.sub.1-6-alkoxy, C.sub.1-6-haloalkoxy, C.sub.1-6-alkylamino-C.sub.1-6-alkoxy, aryl-C.sub.1-6-alkoxy, heterocyclyl-C.sub.1-6-alkoxy, cycloalkyl-C.sub.1-6-alkoxy, heterocyclyl-C.sub.1-6-(hydroxyalkoxy), cycloalkyl-C.sub.1-6-(hydroxyalkoxy), aryl-C.sub.1-6-(hydroxyalkoxy), C.sub.1-6-alkoxyalkoxy, aryloxy-C.sub.1-6-alkoxy, heterocyclyloxy-C.sub.1-6-alkoxy, cycloalkyloxy-C.sub.1-6-alkoxy, aryloxy, heterocyclyloxy, and cycloalkyloxy; wherein R.sup.11 is selected from amino, alkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl and H; wherein A is ##STR00979## wherein X is selected from O, S, NR.sup.2 and CR.sup.3R.sup.4; wherein Y is selected from --NR.sup.b(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.O)(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.O)NR.sup.b(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.O)(CR.sup.3R.sup.4).sub.pO--, --NR.sup.bC(.dbd.O)O(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.S)(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.NR.sup.a)(CR.sup.3R.sup.4).sub.p--, --NR.sup.bSO.sub.2--(CR.sup.3R.sup.4).sub.p--, --OC(.dbd.O)(CR.sup.3R.sup.4).sub.p--, --O(CR.sup.3R.sup.4).sub.p--, --(CR.sup.3R.sup.4).sub.p--S(.dbd.O).sub.p--, --(CR.sup.3R.sup.4).sub.p--, --S(.dbd.O).sub.2NR.sup.b(CR.sup.3R.sup.4).sub.p--, --S(.dbd.O).sub.p(CR.sup.3R.sup.4).sub.p--, --C(.dbd.O)(CR.sup.3R.sup.4).sub.p--, --C(.dbd.O)S(CR.sup.3R.sup.4).sub.p--, --C(.dbd.NR.sup.a)NR.sup.b(CR.sup.3R.sup.4).sub.p--, --C(.dbd.S)NH(CR.sup.3R.sup.4).sub.p-- and --C(.dbd.O)NR.sup.b(CR.sup.3R.sup.4).sub.p--; wherein Y is in either direction; wherein R.sup.a and R.sup.b is each independently selected from H, alkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, R.sup.5R.sup.5N--(C.dbd.O)--, and R.sup.5--(.dbd.O)--; wherein each of R.sup.a and R.sup.b is optionally substituted; wherein R.sup.c, R.sup.d, R.sup.e and R.sup.f is each independently selected from H, and C.sub.1-3-alkyl; wherein each of R.sup.c, R.sup.d, R.sup.c and R.sup.f is optionally substituted; wherein R.sup.2 is selected from H, alkyl, haloalkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl and R.sup.5-carbonyl; wherein R.sup.3 and R.sup.4 is each independently selected from H, alkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, R.sup.6 and alkyl substituted with R.sup.6; wherein R.sup.5 is selected from H, alkyl, haloalkyl, arylalkyl, heterocyclylalkyl, cycloalkylalkyl, aryl, heterocyclyl, alkenyl, alkynyl and cycloalkyl; wherein R.sup.6 is selected from cyano, --OR.sup.2, --SR.sup.2, halo, --SO.sub.2R.sup.2, --C(.dbd.O)R.sup.2, --SO.sub.2NR.sup.2R.sup.5, --NR.sup.5C(.dbd.O)OR.sup.2, --NR.sup.5C(.dbd.O)NR.sup.5R.sup.2, --NR.sup.5C(.dbd.O)R.sup.2, --CO.sub.2R.sup.2, --C(.dbd.O)NR.sup.2R.sup.5 and --NR.sup.2R.sup.5; wherein R.sup.7 is selected from H, halo and C.sub.1-3-alkyl; wherein R.sup.10 is one or more substituents selected from C.sub.1-6-alkoxy, C.sub.1-6-haloalkoxy, C.sub.1-6-alkylamino-C.sub.1-6-alkoxy, aryl-C.sub.1-6-alkoxy, heterocyclyl-C.sub.1-6-alkoxy, cycloalkyl-C.sub.1-6-alkoxy, heterocyclyl-C.sub.1-6-(hydroxyalkoxy), cycloalkyl-C.sub.1-6-(hydroxyalkoxy), aryl-C.sub.1-6-(hydroxyalkoxy), C.sub.1-6-alkoxyalkoxy, aryloxy-C.sub.1-6-alkoxy, heterocyclyloxy-C.sub.1-6-alkoxy, cycloalkyloxy-C.sub.1-6-alkoxy, aryloxy, heterocyclyloxy, and cycloalkyloxy; where p is 0, 1, 2, or 3; and wherein t is 0, 1 or 2; wherein each alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, alkynyl, heterocyclyl, and alkoxy moiety of any R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.a and R.sup.b is optionally substituted with one or more groups selected from halo, --NH.sub.2, --OH, --CO.sub.2H, (C.sub.1-C.sub.6)alkylamino, (C.sub.1-C.sub.6)alkyl, C.sub.1-C.sub.6)alkoxy, C.sub.1-C.sub.6)haloalkyl, di(C.sub.1-C.sub.6)alkylamino, (C.sub.1-C.sub.6)alkylamino-(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)hydroxyalkylamino, (C.sub.1-C.sub.6)alkylamino-(C.sub.1-C.sub.6)alkylamino, phenyl, and heterocyclyl; and pharmaceutically acceptable derivatives thereof; provided R is not methyl when Y is --CO.sub.2-- or --O--; further provided R is not H when Y is (CH.sub.2).sub.0 when A is naphthyl or quinolinyl.

2. Compound of claim 1 wherein R is selected from H, 6-10 membered aryl, 4-10 membered heterocyclyl, 4-6 membered cycloalkyl, C.sub.1-6-alkyl, C.sub.2-6-alkenyl and C.sub.2-6-alkynyl; wherein R is substituted or unsubstituted.

3. Compound of claim 1 wherein R is optionally substituted phenyl or optionally substituted naphthyl.

4. Compound of claim 1 wherein R is a substituted or unsubstituted heterocyclyl ring selected from pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, isoquinolinyl, tetrahydrofuryl, 2,3-dihydrothiazolyl, 2,3-dihydrobenzofuryl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, benzisoxazolyl, benzthiazolyl, benzimidazolyl, benzothiadiazolyl, indolinyl, imidazo[1,2-a]pyridyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl, and thienyl.

5. Compound of claim 1 wherein R is 4-6 membered cycloalkyl selected from 1-methyl-cyclopropyl, cyclopropyl, 2-fluorocyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

6. Compound of claim 1 wherein R is selected from methyl, trifluoromethyl, ethyl, propyl, butyl and pentyl.

7. Compound of claim 1 wherein R is selected from cyclohexenyl, ethenyl and propenyl.

8. Compound of claim 1 wherein R is H.

9. Compound of claim 1 wherein R is dimethylamino.

10. Compound of claim 1 wherein R.sup.1 is selected from ##STR00980## wherein ring T is selected from phenyl and 5-6-membered heteroaryl; wherein Z is selected from N or CH; wherein R.sup.10 is one or more substituents selected from R.sup.8O--; and wherein R.sup.8 is selected from C.sub.1-6-alkyl, C.sub.1-6-haloalkyl, C.sub.1-6-alkylamino-C.sub.1-6-alkyl, aryl-C.sub.1-6-alkyl, heterocyclyl-C.sub.1-6-alkyl, cycloalkyl-C.sub.1-6-alkyl, heterocyclyl-C.sub.1-6-(hydroxyalkyl), cycloalkyl-C.sub.1-6-(hydroxyalkyl), aryl-C.sub.1-6-(hydroxyalkyl), C.sub.1-6-alkoxyalkyl, aryloxy-C.sub.1-6-alkyl, heterocyclyloxy-C.sub.1-6-alkyl, cycloalkyloxy-C.sub.1-6-alkyl, aryl, heterocyclyl, and cycloalkyl.

11. Compound of claim 1 wherein R.sup.1 is selected from ##STR00981## and wherein R.sup.10 is selected from C.sub.1-3-alkoxy, C.sub.1-3-alkylamino-C.sub.1-3-alkoxy, 5-6 membered heterocyclyl-C.sub.1-3-alkoxy, C.sub.4-6-cycloalkyl-C.sub.1-3-alkoxy, 5-6 membered heterocyclyl-C.sub.1-3-(hydroxyalkoxy), C.sub.3-6-cycloalkyl-C.sub.1-3-(hydroxyalkoxy), phenyl-C.sub.1-3-(hydroxyalkoxy), C.sub.1-2-alkoxy-C.sub.1-3-alkoxy, phenyloxy-C.sub.1-3-alkoxy, 5-6 membered heterocyclyloxy-C.sub.1-4-alkoxy, cycloalkyloxy-C.sub.1-3-alkoxy, 5-6 membered heterocyclyloxy, and C.sub.3-6-cycloalkyloxy.

12. Compound of claim 1 wherein R.sup.1 is selected from pyrrolo[2,3-d]pyrimidin-4-yl, pyrazolo[3,4-b]pyridine-4-yl, 2-aminocarbonyl-4-pyridyl, 2-methylaminocarbonyl-4-pyridyl, 2-methylaminopyrimidin-4-yl, 2-aminopyrimidin-4-yl, 6,7-dimethoxy-4-quinolinyl, 6-methoxy-7-(dimethylaminopropoxy)-4-quinolinyl, 6-methoxy-7-(4-morpholinylpropoxy)-4-quinolinyl, 6,7-dimethoxy-4-quinazolinyl, and 6-methoxy-7-(dimethylaminopropoxy)-4-quinazolinyl.

13. Compound of claim 1 wherein Y is selected from --NH(CH.sub.2).sub.p--, --NHC(.dbd.O)(CH.sub.2).sub.p--, --NHC(.dbd.O)(CH.sub.2).sub.p--, --NHC(.dbd.O)O(CH.sub.2).sub.p--, --(CH.sub.2).sub.p--NHC(.dbd.O)--, --NHC(.dbd.O)NH--, --C(.dbd.O)O--, --NHSO.sub.2--, and --C(.dbd.O)NH(CH.sub.2).sub.p--; and wherein p is 0, 1, or 2.

14. Compound of claim 1 wherein Y is selected from --NH--, --NHCH.sub.2--, --NH(CH.sub.2).sub.3--, --NH(CH.sub.2).sub.3--, --NHC(.dbd.O)CH.sub.2--, --NHC(.dbd.O)(CH.sub.2).sub.2--, --NHC(.dbd.O)--, --NHC(.dbd.O)CH.sub.2O--, --NHC(.dbd.O)OCH.sub.2--, --NHC(.dbd.O)NH--, --(CH.sub.2)NHC(.dbd.O)--, --C(.dbd.O)O--, --NHSO.sub.2--, and --C(.dbd.O)NHCH.sub.2--.

15. Compound of claim 1 wherein R is selected from ethyl, isopropyl, (CH.sub.3).sub.3CCH.sub.2--, ethenyl, and an unsubstituted or substituted ring selected from phenyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-pyrrolidinyl, 2-pyrrolyl, 5-imidazolyl, 5-pyrazolyl, 2-pyrazinyl, 4-pyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 8-quinolinyl, 2,3-dihydrobenzofur-7-yl, 2,3-dihydro-1,4-benzodioxin-5-yl, 1,3-benzodioxol-4-yl, 4-isoxazolyl, 3-isothiazolyl, 5-oxazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3-furanyl, 3-thienyl and 2-thienyl; wherein A is naphthyl; wherein X is --O-- or --CH.sub.2--; wherein Y is selected from --NHC(.dbd.O)--, --NHC(.dbd.O)(CH.sub.2)--, --NHC(.dbd.O)(CH.sub.2).sub.2--, --(CH.sub.2).sub.p--NHC(.dbd.O)--, --NHC(.dbd.O)N-- and --NHSO.sub.2--; and wherein R.sup.1 is selected from 6,7-dimethoxy-4-quinolinyl, 6-methoxy-7-(dimethylaminopropoxy)-4-quinolinyl, 6,7-dimethoxy-4-quinazolinyl, and 6-methoxy-7-(dimethylaminopropoxy)-4-quinazolinyl; and pharmaceutically acceptable derivatives thereof.

16. A compound of claim 1 having the following formula IV ##STR00982## wherein Y.sup.a is selected from --(CH.sub.2).sub.p--NH--, --(CH.sub.2).sub.p--C(.dbd.O)NH--, --(CH.sub.2).sub.p--OC(.dbd.O)NH--, --C(.dbd.O)O--, and --C(.dbd.O)NH(CH.sub.2).sub.p--; wherein p is 0, 1, 2, or 3; wherein Z is CR.sup.x or N; wherein R' is selected from H, C.sub.1-5-alkyl, C.sub.1-3-haloalkyl, C.sub.1-3-alkoxy-C.sub.1-3-alkyl, C.sub.1-3-alkoxycarbonyl-C.sub.1-3-alkyl, C.sub.1-5-cyanoalkyl, aminocarbonyl-C.sub.1-5-alkyl, C.sub.1-5-alkyl-aminocarbonyl-C.sub.1-5-alkyl, amino-C.sub.1-5-alkyl, C.sub.1-5-alkyl-amino-C.sub.1-5-alkyl, C.sub.1-5-alkylsolfonyl-C.sub.1-5-alkyl, phenyl-C.sub.1-3-alkyl, C.sub.3-6-cycloalkyl-C.sub.1-3-alkyl, 5-6-membered heterocyclyl-C.sub.1-3-alkyl, and an unsubstituted or substituted ring selected from phenyl, naphthyl, 1,3-benzodioxolyl, C.sub.3-6-cycloalkyl, C.sub.5-6-cycloalkenyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, dihydrothiazolyl, 2,3-dihydrobenzofuryl, 2,3-dihydro-1,4-benzodioxinyl, piperidinyl, 1-methyl-oxopyridyl, tetrahydropyran-4-yl, indolinyl, imidazo[1,2-a]pyridinyl, quinolinyl, benzofuryl, benzo[1,2,5]thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl and thienyl; wherein R.sup.8 is selected from H, fluoro, chloro and methyl; wherein R.sup.9 is selected from H, methyl and fluoro; and wherein R.sup.x is selected from H, CN, NH.sub.2, F, alkylcarbonylamino, and alkylaminocarbonyl; wherein R.sup.10a is H or methoxy; and wherein R.sup.10b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl)propoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(1,2,4-triazol-1-yl)propoxy, triazinylpropoxy, 3-(piperidin-4-yl)propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy; and pharmaceutically acceptable derivatives thereof.

17. Compound of claim 16 wherein Z is CH; wherein R.sup.10a is methoxy; and wherein R.sup.10b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl)propoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(1,2,4-triazol-1-yl)propoxy, triazinylpropoxy, 3-(piperidin-4-yl)propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy.

18. Compound of claim 16 wherein R' is selected from H, methyl, ethyl, n-butyl, isobutyl, tert-butyl, isopropyl, propyl, cyanomethyl, aminocarbonylmethyl, dimethylaminocarbonylmethyl, dimethylaminoethyl, 2-methoxy-1-methylethyl, methoxycarbonylmethyl, methoxyethyl, methoxypropyl, methylsulfonylethyl, dimethylaminoethyl, methoxycarbonylmethyl, ethenyl, thiazol-2-yl-CH(CH.sub.3)--, phenyl-CH(CH.sub.3)--, 5-methylisoxazol-3-ylmethyl, pyrrolidin-1-ylethyl, tetrahydrofur-2-ylmethyl, 4-methyl-2-oxo-oxazolidin-5-yl, pyrid-4-ylmethyl, pyrid-2-ylmethyl, 2-trifluoromethylpyrid-5-ylmethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, (CH.sub.3).sub.3CCH.sub.2--, pentafluoroethyl, CF.sub.3CH.sub.2CH.sub.2--, cyclopropylmethyl, benzyl, 4-methylbenzyl, 4-chlorobenzyl, (2-methoxyphenyl)ethyl, 1-phenylethyl, phenylethyl, cyclopropyl, 1-methylcyclopropyl, 2-fluorocyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5,5-dimethyl-3-oxocyclohexenyl, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 4-ethylphenyl, 3-ethylphenyl, 2-ethylphenyl, 4-isopropylphenyl, 4-isopropyl-3-methylphenyl, 3-isopropylphenyl, 4-tert-butylphenyl, 2,3-dimethylphenyl, 3-fluorophenyl, 4-fluorophenyl, 2-fluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 3,5-difluorophenyl, 2,4,6-trifluorophenyl, 3-bromophenyl, 4-bromophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2-methoxyphenyl, 3,4-dimethoxyphenyl, 2,6-dichlorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5-methoxyphenyl, 4-chloro-2-methoxyphenyl, 2,4-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2-ethoxyphenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 2,5-dichlorophenyl, 2,4-dichlorophenyl, 2,3-dichlorophenyl, 3,5-dichlorophenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-di(trifluoromethyl)-phenyl, 3,5-di(trifluoromethyl)-2-methylphenyl, 4-dimethylaminophenyl, 3-dimethylaminophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-cyanophenyl, 4-methylthiophenyl, 3-methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 4-[1-isopropylpiperazinin-4-yl]phenyl, 2-[(1-methylpyrrolidin-3-yl)--N(CH.sub.3)]-5-trifluoromethylphenyl, 5-[1-methylpiperazin-4-ylmethyl]-3-trifluoromethylphenyl, 5-[2-oxopyrrolidin-1-yl]-3-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-bromo-2-fluorophenyl, 2-trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 4-pentafluoroethylphenyl, -fluoro-3-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5-trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 2-[methylcarbonylamino]-5-trifluoromethylphenyl, 3-[1-methylpiperidin-4-yl]-5-trifluoromethylphenyl, 2-[1,1-dioxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2-[1-oxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2-[thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2-(3-dimethylaminopropyl)methylamino]-5-trifluoromethylphenyl, 2-[(3-dimethylamino-pyrroldin-1-yl)-5-trifluoromethylphenyl, 3-(methylcarbonylamino)phenyl, 3-(4-methylpiperazin-1-ylmethyl)phenyl, 2-(4-methylpiperazin-1-ylmethyl)phenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2-[1-methylpiperidin-4-yloxy]-5-trifluoromethylphenyl, 2-methoxy-5-trifluoromethylphenyl, 2-methoxy-5-phenylphenyl, 2-[3,3-dimethyl-2-oxo-azetidin-1-yl]-5-trifluoromethylphenyl, 2-[morpholin-4-ylethoxy]-5-tert-butylphenyl, 2-methoxy-5-fluorophenyl, 2-methoxy-5-tert-butylphenyl, 3-[dimethylaminomethylcarbonylamino]-4-tert-butylphenyl, 2-methoxy-5-[2-pyridylaminocarbonyl]phenyl, 2-methoxy-5-phenylaminocarbonylphenyl, 2-[methyl-(1-methylpyrrolidin-3-yl)amino]-5-trifluoromethylphenyl, 2,2-difluorobenzodioxol-4-yl, biphenyl, 2-naphthyl, 2,3-dihydro-1,4-benzodioxin-6-yl, 7-fluoro-2,3-dihydro-1,4-benzodioxin-6-yl, 1,3-benzodioxol-4-yl, 1-isopropylpiperidin-4-yl, 2-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 4-piperazinyl, 1-methylpiperidin-4-yl, 3-methyl-isothiazol-5-yl, 3-isothiazolyl, 4,5-dichloro-3-isothiazolyl, isoxazol-3-yl, 5-isoxazolyl, 4-isoxazolyl, 5-methyl-isoxazol-3-yl, 3,5-dimethyl-isoxazol-4-yl, 4,5-dimethyl-isoxazol-3-yl, 3-methyl-isoxazol-5-yl, 5-tert-butyl-isoxazol-3-yl, 4-bromo-5-methyl-isoxazol-3-yl, 5-oxazolyl, 1-methylimidazol-5-yl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-methylcarbonyl-thien-3-yl, 2-methylcarbonyl-5-tert-butyl-thien-3-yl, 2-aminocarbonyl-5-tert-butyl-thien-3-yl, 4-methoxy-5-chloro-3-thienyl, 3-methyl-2-thienyl, 5-methyl-2-thienyl, 5-methylthio-2-thienyl, 5-methylsulfonyl-2-thienyl, 3-ethoxy-2-thienyl, 3-chloro-2-thienyl, 5-chloro-2-thienyl, 3-bromo-2-thienyl, 5-bromo-2-thienyl, 4-methoxy-5-bromo-3-thienyl, 4-methoxy-3-thienyl, 2-furyl, 2-cyano-5-phenylfur-3-yl, 4,5-dimethyl-2-furyl, 5-methyl-2-trifluoromethyl-3-furyl, 3-furanyl, 1-methylpyrrol-2-yl, 2-pyrrolyl, 2-pyrazinyl, 5-methyl-2-pyrazinyl, 4-pyrimidinyl, 2,6-dimethoxy-4-pyrimidinyl, 4-methoxy-6-methylpyrimidin-2-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-trifluoromethylpyridin-2-yl, 2-trifluoromethylpyridin-5-yl, 2-dimethylaminopyridin-5-yl, 5-chloro-2-pyridyl, 2-fluoro-3-pyridyl, 2-chloro-3-pyridyl, 2-methoxy-3-pyridyl, 2-ethoxy-3-pyridyl, 2-chloro-4-pyridyl, 2,5-dichloro-3-pyridyl, 2-(dimethylaminoethoxy)-3-pyridyl, 2-methoxy-5-pyridyl, 2-methyl-5-pyridyl, 4-chloro-2-pyridyl, 4-methoxy-5-pyridyl, 3-benzyloxypyridin-2-yl, 4-methylpyridin-2-yl, 4-ethylpyridin-2-yl, 2-chloropyridin-4-yl, 3-chloropyridin-5-yl, 3-chloropyridin-6-yl, 2-chloropyridin-5-yl, 4-chloropyridin-2-yl, 1-methyl-2-oxopyrid-5-yl, tetrahydropyran-4-yl, 4,5-dihydrothiazol-2-yl, thiazol-2-yl, 5-methyl-thiazol-2-yl, 4,5-dimethyl-thiazol-2-yl, 4-tert-butyl-thiazol-2-yl, 5-tert-butyl-thiazol-2-yl, 5-nitrothiazol-2-yl, 5-bromothiazol-2-yl, 5-[4-chlorophenyl]-thiazol-2-yl, 4-[4-chlorophenyl]-thiazol-2-yl, 4-[4-nitrophenyl]-thiazol-2-yl, 4-thiazolyl, 2-methyl-4-thiazolyl, 2,5-dimethyl-4-thiazolyl, 2,4-dimethyl-5-thiazolyl, 5-tert-butyl-1,3,4-thiadiazol-2-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5-ethyl-1,3,4-thiadiazol-2-yl, pyrazol-5-yl, 3-pyrazolyl, 1,3-diphenyl-pyrazol-3-yl, 1,3-dimethyl-pyrazol-3-yl, 5-cyano-4-tert-butyl-pyrazol-3-yl, 5-amino-3-methyl-pyrazol-1-yl, 3-methyl-1-tert-butyl-pyrazol-3-yl, 5-amino-3-tert-butyl-pyrazol-1-yl, 1-ethylpyrazol-5-yl, 3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-pyrazol-5-yl, 4,4-dimethyl-1,2,34-tetrahydroisoquinolin-7-yl, 7-quinolinyl, 2,3-dihydrobenzofur-7-yl, 3,3-dimethyl-1-methylcarbonylindolin-6-yl, 3,3-dimethyl-2,3-dihydro-indol-6-yl, 4-tert-butyl-imidazo[1,2-a]pyridin-6-yl, 3-quinolinyl, 2-benzofuryl, benzo[1,2,5]thiadiazol-4-yl, 7-methyl-benzothiazol-2-yl, 6-ethoxy-benzothiazol-2-yl, 6-fluoro-benzothiazol-2-yl, 5,6-dimethyl-benzothiazol-2-yl, benzimidazol-2-yl, 1-methyl-benzimidazol-2-yl, benzoxazol-2-yl, benzisoxazol-3-yl, 4-methoxybenzisoxazol-3-yl and 2-methylbenzothiazol-5-yl and pharmaceutically acceptable derivatives thereof.

19. Compound of claim 16 wherein R' is selected from H, isopropyl, (CH.sub.3).sub.3CCH.sub.2--, benzyl, 4-methylphenylmethyl, 2-thiazolyl-CH(CH.sub.3)--, phenyl-CH(CH.sub.3)--, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 4-tert-butyl-phenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, -chloro-3-trifluoromethylphenyl, 4-dimethylaminophenyl, biphenyl, 3-isothiazolyl, and 2-thiazolyl; and pharmaceutically acceptable derivatives thereof.

20. Compound of claim 16 wherein Y.sup.a is --C(.dbd.O)NH--.

21. Compound of claim 16 wherein R.sup.8 and R.sup.9 are both H.

22. Compound of claim 16 and pharmaceutically acceptable salts thereof selected from 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-phenyl-2,3-dihydro-4H-1,4-benz- oxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(4-methylphenyl)-2,3-dihydro-4- H-1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(4-dimethylamino)-2,3-dihydro-- 4H-1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(4-trifluoromethyl)phenyl)-2,3- -dihydro-4H-1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-((1S)-1-phenylethyl)-2,3-dihyd- ro-4H-1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(4-chlorophenyl)-2,3-dihydro-4- H-1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(4-trifluoromethyl)phenyl)-2,3- -dihydro-4H-1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(4-(1,1-dimethylethyl)phenyl)-- 2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(3-isoxazolyl)-2,3-dihydro-4H-- 1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(3-isoxazolyl)-2,3-dihydro-4H-- 1,4-benzoxazine-4-carboxamide; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-2,3-dihydro-4- H-1,4-benzoxazine-4-carboxamide; and 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(3-chlorophenyl)-2,3-dihydro-4- H-1,4-benzoxazine-4-carboxamide.

23. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of claim 1.

Description

FIELD OF THE INVENTION

This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating inflammation, angiogenesis and cancer.

BACKGROUND OF THE INVENTION

Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. A partial list of such kinases includes ab1, Akt, bcr-ab1, Blk, Brk, Btk, c-kit, c-Met, c-src, c-fms, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70. Inhibition of such kinases has become an important therapeutic target.

Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularisation, such as retinopathies (including diabetic retinopathy), age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis), or other chronic inflammatory disorders, such as chronic asthma, arterial or post-transplantational atherosclerosis, endometriosis, and neoplastic diseases, for example so-called solid tumors and liquid tumors (such as leukemias).

At the center of the network regulating the growth and differentiation of the vascular system and its components, both during embryonic development and normal growth, and in a wide number of pathological anomalies and diseases, lies the angiogenic factor known as Vascular Endothelial Growth Factor" (VEGF; originally termed `Vascular Permeability Factor", VPF), along with its cellular receptors (see G. Breier et al., Trends in Cell Biology, 6:454-456 (1996)).

VEGF is a dimeric, disulfide-linked 46-kDa glycoprotein related to "Platelet-Derived Growth Factor" (PDGF); it is produced by normal cell lines and tumor cell lines; is an endothelial cell-specific mitogen; shows angiogenic activity in in vivo test systems (e.g. rabbit cornea); is chemotactic for endothelial cells and monocytes; and induces plasminogen activators in endothelial cells, which are involved in the proteolytic degradation of extracellular matrix during the formation of capillaries. A number of isoforms of VEGF are known, which show comparable biological activity, but differ in the type of cells that secrete them and in their heparin-binding capacity. In addition, there are other members of the VEGF family, such as "Placenta Growth Factor" (PlGF) and VEGF-C.

VEGF receptors (VEGFR) are transmembranous receptor tyrosine kinases. They are characterized by an extracellular domain with seven immunoglobulin-like domains and an intracellular tyrosine kinase domain. Various types of VEGF receptor are known, e.g. VEGFR-1 (also known as flt-1), VEGFR-2 (also known as KDR), and VEGFR-3.

A large number of human tumors, especially gliomas and carcinomas, express high levels of VEGF and its receptors. This has led to the hypothesis that the VEGF released by tumor cells stimulates the growth of blood capillaries and the proliferation of tumor endothelium in a paracrine manner and through the improved blood supply, accelerate tumor growth. Increased VEGF expression could explain the occurrence of cerebral edema in patients with glioma. Direct evidence of the role of VEGF as a tumor angiogenesis factor in vivo is shown in studies in which VEGF expression or VEGF activity was inhibited. This was achieved with anti-VEGF antibodies, with dominant-negative VEGFR-2 mutants which inhibited signal transduction, and with antisense-VEGF RNA techniques. All approaches led to a reduction in the growth of glioma cell lines or other tumor cell lines in vivo as a result of inhibited tumor angiogenesis.

Angiogenesis is regarded as an absolute prerequisite for tumors which grow beyond a diameter of about 1-2 mm; up to this limit, oxygen and nutrients may be supplied to the tumor cells by diffusion. Every tumor, regardless of its origin and its cause, is thus dependent on angiogenesis for its growth after it has reached a certain size.

Three principal mechanisms play an important part in the activity of angiogenesis inhibitors against tumors: 1) Inhibition of the growth of vessels, especially capillaries, into avascular resting tumors, with the result that there is no net tumor growth owing to the balance that is achieved between cell death and proliferation; 2) Prevention of the migration of tumor cells owing to the absence of blood flow to and from tumors; and 3) Inhibition of endothelial cell proliferation, thus avoiding the paracrine growth-stimulating effect exerted on the surrounding tissue by the endothelial cells which normally line the vessels. See R. Connell and J. Beebe, Exp. Opin. Ther. Patents, 11:77-114 (2001).

VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hyperpermeability and the formation of edema. Indeed, vascular hyperpermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production.

Inflammatory cytokines stimulate VEGF production. Hypoxia results in a marked upregulation of VEGF in numerous tissues, hence situations involving infarct, occlusion, ischemia, anemia, or circulatory impairment typically invoke VEGF/VPF-mediated responses. Vascular hyperpermeability, associated edema, altered transendothelial exchange and macromolecular extravasation, which is often accompanied by diapedesis, can result in excessive matrix deposition, aberrant stromal proliferation, fibrosis, etc. Hence, VEGF-mediated hyperpermeability can significantly contribute to disorders with these etiologic features. As such, regulators of angiogenesis have become an important therapeutic target.

The hepatocyte growth factor receptor ("c-Met") is a unique receptor tyrosine kinase shown to be overexpressed in a variety of malignancies. c-Met typically comprises, in its native form, a 190-kDa heterodimeric (a disulfide-linked 50-kDa .alpha.-chain and a 145-kDa .beta.-chain) membrane-spanning tyrosine kinase protein (Proc. Natl. Acad. Sci. USA, 84:6379-6383 (1987)). c-Met is mainly expressed in epithelial cells and stimulation of c-Met leads to scattering, angiogenesis, proliferation and metastasis. (See Cytokine and Growth Factor Reviews, 13:41-59 (2002)).

The ligand for c-Met is hepatocyte growth factor (also known as scatter factor, HGF and SF). HGF is a heterodimeric protein secreted by cells of mesodermal origin (Nature, 327:239-242 (1987); J. Cell Biol., 111:2097-2108 (1990)).

Various biological activities have been described for HGF through interaction with c-met (Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the c-Met Receptor, Goldberg and Rosen, eds., Birkhauser Verlag-Basel, 67-79 (1993). The biological effect of HGF/SF may depend in part on the target cell. HGF induces a spectrum of biological activities in epithelial cells, including mitogenesis, stimulation of cell motility and promotion of matrix invasion (Biochem. Biophys. Res. Comm., 122:1450-1459 (1984); Proc. Natl. Acad. Sci. U.S.A., 88:415-419 (1991)). It stimulates the motility and invasiveness of carcinoma cells, the former having been implicated in the migration of cells required for metastasis. HGF can also act as a "scatter factor", an activity that promotes the dissociation of epithelial and vascular endothelial cells (Nature, 327:239-242 (1987); J. Cell Biol., 111:2097-2108 (1990); EMBO J., 10:2867-2878 (1991); Proc. Natl. Acad. Sci. USA, 90:649-653 (1993)). Therefore, HGF is thought to be important in tumor invasion (Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the C-Met Receptor, Goldberg and Rosen, eds., Birkhauser Verlag-Basel, 131-165 (1993)).

HGF and c-Met are expressed at abnormally high levels in a large variety of solid tumors. High levels of HGF and/or c-Met have been observed in liver, breast, pancreas, lung, kidney, bladder, ovary, brain, prostate, gallbladder and myeloma tumors in addition to many others. The role of HGF/c-Met in metastasis has been investigated in mice using cell lines transformed with HGF/c-Met (J. Mol. Med., 74:505-513 (1996)). Overexpression of the c-Met oncogene has also been suggested to play a role in the pathogenesis and progression of thyroid tumors derived from follicular epithelium (Oncogene, 7:2549-2553 (1992)). HGF is a morphogen (Development, 110:1271-1284 (1990); Cell, 66:697-711 (1991)) and a potent angiogenic factor (J. Cell Biol., 119:629-641 (1992)).

Recent work on the relationship between inhibition of angiogenesis and the suppression or reversion of tumor progression shows great promise in the treatment of cancer (Nature, 390:404-407 (1997)), especially the use of multiple angiogenesis inhibitors compared to the effect of a single inhibitor. Angiogenesis can be stimulated by HGF, as well as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).

Angiogenesis, the process of sprouting new blood vessels from existing vasculature and arteriogenesis, the remodeling of small vessels into larger conduit vessels are both physiologically important aspects of vascular growth in adult tissues. These processes of vascular growth are required for beneficial processes such as tissue repair, wound healing, recovery from tissue ischemia and menstrual cycling. They are also required for the development of pathological conditions such as the growth of neoplasias, diabetic retinopathy, rheumatoid arthritis, psoriasis, certain forms of macular degeneration, and certain inflammatory pathologies. The inhibition of vascular growth in these contexts has also shown beneficial effects in preclinical animal models. For example, inhibition of angiogenesis by blocking vascular endothelial growth factor or its receptor has resulted in inhibition of tumor growth and in retinopathy. Also, the development of pathological pannus tissue in rheumatoid arthritis involves angiogenesis and might be blocked by inhibitors of angiogenesis.

The ability to stimulate vascular growth has potential utility for treatment of ischemia-induced pathologies such as myocardial infarction, coronary artery disease, peripheral vascular disease, and stroke. The sprouting of new vessels and/or the expansion of small vessels in ischemic tissues prevents ischemic tissue death and induces tissue repair. Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularization, such as retinopathies (including diabetic retinopathy), age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis), or other chronic inflammatory disorders, such as chronic asthma, arterial or post-transplantational atherosclerosis, endometriosis, and neoplastic diseases, for example so-called solid tumors and liquid tumors (such as leukemias). Treatment of malaria and related viral diseases may also be mediated by HGF and cMet.

Elevated levels of HGF and c-Met have also been observed in non-oncological settings, such as hypertension, myocardial infarction and rheumatoid arthritis. It has been observed that levels of HGF increase in the plasma of patients with hepatic failure (Gohda et al., supra) and in the plasma (Hepatol., 13:734-750 (1991)) or serum (J. Biochem., 109:8-13 (1991)) of animals with experimentally induced liver damage. HGF has also been shown to be a mitogen for certain cell types, including melanocytes, renal tubular cells, keratinocytes, certain endothelial cells and cells of epithelial origin (Biochem. Biophys. Res. Commun., 176:45-51 (1991); Biochem. Biophys. Res. Commun., 174:831-838 (1991); Biochem., 30:9768-9780 (1991); Proc. Natl. Acad. Sci. USA, 88:415-419 (1991)). Both HGF and the c-Met protooncogene have been postulated to play a role in microglial reactions to CNS injuries (Oncogene, 8:219-222 (1993)).

In view of the role of HGF and/or c-Met in potentiating or promoting such diseases or pathological conditions, it would be useful to have a means of substantially reducing or inhibiting one or more of the biological effects of HGF and its receptor. Thus a compound that reduces the effect of HGF would be a useful compound.

T cells play a pivotal role in the regulation of immune responses and are important for establishing immunity to pathogens. In addition, T cells are often activated during inflammatory autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease, type I diabetes, multiple sclerosis, Sjogren's disease, myasthenia gravis, psoriasis, and lupus. T cell activation is also an important component of transplant rejection, allergic reactions, and asthma.

T cells are activated by specific antigens through the T cell receptor (TCR) which is expressed on the cell surface. This activation triggers a series of intracellular signaling cascades mediated by enzymes expressed within the cell (Kane, L P et al. Current Opinion in Immunol. 200, 12, 242). These cascades lead to gene regulation events that result in the production of cytokines, like interleukin-2 (IL-2). IL-2 is a critical cytokine in T cell activation, leading to proliferation and amplification of specific immune responses.

One class of enzymes shown to be important in signal transduction is the kinase enzymes Members of the Src-family of tyrosine kinases include, for example: Lck, Fyn(B), Fyn(T), Lyn, Src, Yes, Hck, Fgr and Blk (for review see: Bolen, J B, and Brugge, J S Annu. Rev. Immunol 1997, 15, 371). Gene disruption studies suggest that inhibition of some members of the src family of kinases would potentially lead to therapeutic benefit. Src(-/-) mice have abnormalities in bone remodeling or osteopetrosis (Soriano, P. Cell 1991, 64, 693), suggesting that inhibition of this kinase might be useful in diseases of bone resorption, such as osteoporosis. Lck(-/-) mice have defects in T cell maturation and activation (Anderson, S J et al. Adv. Immunol. 1994, 56, 151), suggesting that inhibition of this kinase might be useful in diseases of T cell mediated inflammation. In addition, human patients have been identified with mutations effecting Lck kinase activity (Goldman, F D et al. J. Clin. Invest. 1998, 102, 421). These patients suffer from a severe combined immunodeficiency disorder (SCID).

Without wishing to imply that the compounds disclosed in the present invention possess pharmacological activity only by virtue of an effect on a single biological process, it is believed that the compounds modulate T cell activation by way of inhibition of one or more of the multiple protein tyrosine kinases involved in early signal transduction steps leading to T cell activation, for example by way of inhibition of Lck kinase.

Src-family kinases are also important for signaling downstream of other immune cell receptors. Fyn, like Lck, is involved in TCR signaling in T cells (Appleby, M W et al. Cell 1992, 70, 751). Hck and Fgr are involved in Fc.gamma. receptor signaling leading to neutrophil activation (Vicentini, L. et al. J. Immunol. 2002, 168, 6446). Lyn and Src also participate in Fc.gamma. receptor signaling leading to release of histamine and other allergic mediators (Turner, H. and Kinet, J-P Nature 1999, 402, B24). These findings suggest that Src family kinase inhibitors may be useful in treating allergic diseases and asthma.

PCT publication WO 03/000660 describes substituted phenyl compounds. Substituted quinolines are described in U.S. Pat. No. 6,143,764. WO 02/32872 describes substituted quinolines. WO 00/47212 describes substituted quinazoline derivatives.

Compounds of the current invention have not been described for the treatment of cancer and inflammation.

DESCRIPTION OF THE INVENTION

A class of compounds useful in treating cancer and angiogenesis is defined by Formula I

##STR00001##

wherein R is selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, H, substituted or unsubstituted alkyl, and substituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl; wherein R.sup.1 is selected from substituted or unsubstituted 5-14-membered nitrogen containing heterocyclyl; wherein A is an optionally substituted ten membered bicyclic ring comprising at least one aromatic ring; wherein X is selected from O, S, NR.sup.2 and CR.sup.3R.sup.4; wherein Y is selected from --NR.sup.b(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.O)(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.O)NR.sup.b(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.O)(CR.sup.3R.sup.4).sub.pO--, --NR.sup.bC(.dbd.O)O(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.S)(CR.sup.3R.sup.4).sub.p--, --NR.sup.bC(.dbd.NR.sup.a)(CR.sup.3R.sup.4).sub.p--, --NR.sup.bSO.sub.2--(CR.sup.3R.sup.4).sub.p--, --OC(.dbd.O)(CR.sup.3R.sup.4).sub.p--, --O(CR.sup.3R.sup.4).sub.p--, --(CR.sup.3R.sup.4).sub.p--S(.dbd.O).sub.t--, --(CR.sup.3R.sup.4).sub.p--, --S(.dbd.O).sub.2NR.sup.b(CR.sup.3R.sup.4).sub.p--, --S(.dbd.O).sub.t(CR.sup.3R.sup.4).sub.p--, --C(.dbd.O)(CR.sup.3R.sup.4).sub.p--, --C(.dbd.NR.sup.a)NH(CR.sup.3R.sup.4).sub.p--, --C(.dbd.S)NH(CR.sup.3R.sup.4).sub.p-- and --C(.dbd.O)NH(CR.sup.3R.sup.4).sub.p--; wherein Y is in either direction; wherein R.sup.a and R.sup.b is each independently selected from H, alkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, R.sup.5R.sup.5N--(C.dbd.O)--, and R.sup.5--(.dbd.O)--;

wherein each of R.sup.a and R.sup.b is optionally substituted; wherein R.sup.2 is selected from H, alkyl, haloalkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl and R.sup.5-carbonyl; wherein R.sup.3 and R.sup.4 is each independently selected from H, alkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, R.sup.6 and alkyl substituted with R.sup.6; wherein R.sup.5 is selected from H, alkyl, haloalkyl, arylalkyl, heterocyclylalkyl, cycloalkylalkyl, aryl, heterocyclyl, alkenyl, alkynyl and cycloalkyl; wherein R.sup.6 is selected from cyano, --OR.sup.2, --SR.sup.2, halo, --SO.sub.2R.sup.2, --C(.dbd.O)R.sup.2, --SO.sub.2NR.sup.2R.sup.5, --NR.sup.5C(.dbd.O)OR.sup.2, --NR.sup.5C(.dbd.O)NR.sup.5R.sup.2, --NR.sup.5C(.dbd.O)R.sup.2, --CO.sub.2R.sup.2, --C(.dbd.O)NR.sup.2R.sup.5 and --NR.sup.2R.sup.5; wherein p is 0, 1, 2, or 3; and wherein t is 0, 1 or 2; and pharmaceutically acceptable derivatives thereof; provided R is not methyl when Y is --CO.sub.2--.

The invention also relates to compounds of Formula I wherein R is selected from H, 6-10 membered aryl, 4-10 membered heterocyclyl, 4-6 membered cycloalkyl, C.sub.1-6-alkyl, C.sub.2-6-alkenyl and C.sub.2-6-alkynyl; wherein R is substituted or unsubstituted; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is phenyl or n